Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor, Harvard Medical School
Oncology
Dr. Daniel A. Haber, MD
|
|
Give Review
Daniel Haber is an expert in the field of Oncology. He went to medical school at Stanford University School of Medicine. Stanford University School of Medicine is one of the top medical schools in the US. Stanford University School of Medicine has a rank of 2 in research and a 25 in primary care He over the years received 3 awards: "Investigator", "Elected Member" and "Super Doctor". Dr. Daniel A. Haber is also published. He has 99 publications published. The lastest publication: "Correlating chemical sensitivity and basal gene expression reveals mechanism of action.' Daniel Haber accepts all Medicare patients.
Publications
- Correlating chemical sensitivity and basal gene expression reveals mechanism of action.
- Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer.
- Cell fate: Transition loses its invasive edge.
- Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells.
- MAPK7 regulates EMT Features and Modulates the Generation of CTCs.
- Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
- Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models.
- Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.
- Collective and individual migration following the epithelial-mesenchymal transition.
- Brain tumor cells in circulation are enriched for mesenchymal gene expression.
- Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells.
- Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.
- Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.
- A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12.
- Solidifying Liquid Biopsies: Can Circulating Tumor Cell Monitoring Guide Treatment Selection in Breast Cancer?
- Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant.
- Isolation and Molecular Characterization of Circulating Melanoma Cells.
- Microfluidic, marker-free isolation of circulating tumor cells from blood samples.
- Inactivation of the tumor suppressor WTX in a subset of pediatric tumors.
- The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis.
- Dynamic Chromatin Modification Sustains Epithelial-Mesenchymal Transition following Inducible Expression of Snail-1.
- Developing standards for breakthrough therapy designation in oncology.
- TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma.
- Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.
- An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.
- Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer.
- RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis.
- Biopolymer system for cell recovery from microfluidic cell capture devices.
- MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib.
- Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses.
- The WTX Tumor Suppressor Regulates Mesenchymal Progenitor Cell Fate Specification.
- The evolving war on cancer.
- Circulating tumor cells: approaches to isolation and characterization.
- Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers.
- A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration.
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
- Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.
- Amplification-free digital gene expression profiling from minute cell quantities.
- The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes.
- Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network.
- Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.
- A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
- Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin.
- A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression.
- The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity.
- Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
- The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.
- Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line e...
- Modeling oncogene addiction using RNA interference.
- Detection of mutations in EGFR in circulating lung-cancer cells.
- Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites.
- Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.
- Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
- First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
- Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
- Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.
- Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
- Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway.
- The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
- Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor.
- Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
- Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression.
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
- Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene.
- A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors.
- Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.
- Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.
- Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
- An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.
- Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
- A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.
- Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon.
- Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
- Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
- "Oncogenic shock": explaining oncogene addiction through differential signal attenuation.
- Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
- A blood-based test for epidermal growth factor receptor mutations in lung cancer.
- Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or ...
- Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing.
- Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
- Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.
- Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.
- Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
- Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
- Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
- Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
- Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
- Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.
- The EWS-WT1 gene fusion in desmoplastic small round cell tumor.
- Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
- Pulmonary adenocarcinomas with mutant epidermal growth factor receptors.
- SUMO-1 modification of the Wilms' tumor suppressor WT1.
- RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
- Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
- The C. elegans Polycomb gene SOP-2 encodes an RNA binding protein.
- A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Schools
Stanford University
Massachusetts General Hospital
Dana Farber Cancer Institute
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Investigator
- Elected Member
- Super Doctor
Education
-
Massachusetts General Hospital -
Stanford University School of Medicine
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Steven L. McAfee, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Harshabad Singh, MB BS
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arnaud C. Drouin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramesh A. Shivdasani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam F. Binder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alice T. Shaw, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David P. Ryan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin H. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William C. Aird, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Channing Yu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Caron A. Jacobson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vassiliki A. Boussiotis, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jason Luke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monika E. Pilichowska-Roehling, MD
This Doctor is OpenDoctor Recommended.
|